Literature DB >> 29688336

Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.

Mariabeatrice Principi1, Andrea Iannone1, Giuseppe Losurdo1, Michela Mangia1, Endrit Shahini1, Francesca Albano1, Salvatore Fabio Rizzi1, Rosa Federica La Fortezza1, Rosa Lovero1, Antonella Contaldo1, Michele Barone1, Gioacchino Leandro2, Enzo Ierardi1, Alfredo Di Leo1.   

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is common in inflammatory bowel diseases (IBD). Herein, NAFLD prevalence and risk factors in a large IBD cohort were evaluated and compared to that of a non-IBD sample.
Methods: Crohn's disease/ulcerative colitis outpatients referred to IBD service of our Gastroenterology Unit were enrolled. Subjects affected by functional and motor gastrointestinal disorders, in whom IBD was ruled out, referred to general outpatient service in the same area, were considered as nonIBD group. Exclusion criteria were based on previous diagnosis of nonNAFLD chronic liver diseases and secondary causes of fat liver overload. Characteristics of IBD and liver status were collected. Risk factors for metabolic syndrome were analyzed. Ultrasonographic presence and degree of steatosis were assessed. Data were examined by univariate and multivariate analyses.
Results: For this study 465 IBD and 189 non-IBD subjects were consecutively enrolled. NAFLD was found in 28.0% and 20.1% in IBD and non-IBD subjects, respectively (P = 0.04). IBD patients with NAFLD were younger than non-IBD ones. There was no significant difference in steatosis grade and association between NAFLD and IBD behavior, extension, activity, and drugs. In the IBD group, multivariate analysis demonstrated that NAFLD was independently associated to metabolic syndrome (OR=2.24, 95%CI 1.77-28.81), diabetes (OR=1.71, 95%CI 1.43-12.25), fasting blood glucose (OR=1.36, 95%CI 1.13-1.68), and abdominal circumference (OR=1.68, 95%CI 1.15-14.52). Conclusions: NAFLD is more common and occurs at a younger age in IBD than in nonIBD subjects. However, further investigation is required to ascertain possible NAFLD pathogenic IBD-related factors other than conventional/metabolic ones. 10.1093/ibd/izy051_video1izy051.video15774874877001.

Entities:  

Mesh:

Year:  2018        PMID: 29688336     DOI: 10.1093/ibd/izy051

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  18 in total

1.  Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping.

Authors:  Scott McHenry; Yeshika Sharma; Ankita Tirath; Richard Tsai; Aaron Mintz; Tyler J Fraum; Amber Salter; Jeffrey D Browning; Avegail G Flores; Nicholas O Davidson; Kathryn J Fowler; Matthew A Ciorba; Parakkal Deepak
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-12       Impact factor: 11.382

2.  Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Authors:  Mohammad Zamani; Shaghayegh Alizadeh-Tabari; Siddharth Singh; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2022-03-11       Impact factor: 9.524

3.  Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study.

Authors:  Lisa C Adams; Falk Lübbe; Keno Bressem; Moritz Wagner; Bernd Hamm; Marcus R Makowski
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

4.  Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department.

Authors:  Alisa Likhitsup; Jason Dundulis; Shaya Ansari; Hani El-Halawany; Randal Michelson; Colleen Hutton; Kevin Kennedy; John H Helzberg; Rajiv Chhabra
Journal:  Ann Gastroenterol       Date:  2019-03-15

5.  High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy.

Authors:  Alisa Likhitsup; Jason Dundulis; Shaya Ansari; Sruthi Patibandla; Colleen Hutton; Kevin Kennedy; John H Helzberg; Rajiv Chhabra
Journal:  Ann Gastroenterol       Date:  2019-07-22

Review 6.  Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health.

Authors:  Kaitlyn Oliphant; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2019-06-13       Impact factor: 14.650

Review 7.  Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms.

Authors:  Andrew Szilagyi
Journal:  Clin J Gastroenterol       Date:  2019-08-26

8.  Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.

Authors:  Giuseppe Losurdo; Rosa Federica La Fortezza; Andrea Iannone; Antonella Contaldo; Michele Barone; Enzo Ierardi; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

Review 9.  Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling.

Authors:  Sara Della Torre
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

10.  Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Austin Lin; Hannah Roth; Adjoa Anyane-Yeboa; David T Rubin; Sonali Paul
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.